Positive Interim 12-Week Results of ASC41 Trial Presented at EASL Congress 2024

Monday, 10 June 2024, 21:20

The presentation of the Phase II clinical trial results of ASC41 by Gannex at EASL Congress 2024 revealed promising outcomes for patients with biopsy-confirmed MASH. The interim data after 12 weeks indicated significant improvements and provided optimism for the potential effectiveness of ASC41 in treating MASH. The findings showcased a positive trend towards addressing the medical needs of patients with this condition, projecting a hopeful future for improved treatment solutions.
https://store.livarava.com/749ff545-278a-11ef-a412-9d5fa15a64d8.jpg
Positive Interim 12-Week Results of ASC41 Trial Presented at EASL Congress 2024

ASC41 Trial Results at EASL 2024

The recent presentation at EASL Congress 2024 highlighted the interim data from the Phase II clinical trial of ASC41 by Gannex.

Promising Outcomes for MASH Patients

The results showed significant improvements in patients with biopsy-confirmed MASH, indicating the potential effectiveness of ASC41 in addressing this condition.

  • Positive trend: The findings demonstrated a positive trajectory towards meeting the medical needs of MASH patients.

This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.


Related posts


Newsletter

Get the most reliable and up-to-date financial news with our curated selections. Subscribe to our newsletter for convenient access and enhance your analytical work effortlessly.

Subscribe